Dentsply Sirona Inc. key statistics and ratios
In fiscal 2025, Dentsply Sirona Inc. had return on equity of -36.5%, an operating margin of -11.5%, debt equal to 173.9% of equity and a current ratio of 1.51. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.
Financial ratios
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross margin | 51.2% | 50.9% | 50.2% | 53.1% | 53.5% | 54.7% | 56.7% | 53.4% | 54.8% | 51.9% | 53.8% | 49.6% | 55.5% | 54.2% | 52.6% | 51.6% | 50.0% | 49.5% |
| Operating margin | 17.7% | 17.1% | 11.9% | 13.0% | 14.2% | 15.2% | 14.0% | 12.1% | −39.1% | −24.0% | 8.8% | −0.1% | 14.4% | −23.9% | −2.1% | −23.2% | −11.5% | −8.5% |
| Net margin | 12.7% | 12.0% | 9.6% | 10.7% | 10.6% | 11.0% | 9.4% | 11.5% | −38.8% | −25.4% | 6.4% | −2.2% | 9.7% | −24.2% | −3.3% | −24.0% | −16.3% | −15.0% |
| Free-cash-flow margin | 14.2% | 15.0% | 12.7% | 9.5% | 10.8% | 15.8% | 15.9% | 11.7% | 11.5% | 8.0% | 12.8% | 16.8% | 12.2% | 9.4% | 5.8% | 7.4% | 2.8% | 3.9% |
| Return on equity | 15.0% | 14.5% | 13.3% | 15.5% | 13.2% | 13.3% | 10.8% | 8.2% | −21.0% | −17.2% | 5.0% | −1.5% | 8.3% | −21.6% | −3.7% | −34.8% | −36.5% | −40.6% |
| Return on assets | 8.9% | 8.4% | 6.1% | 6.5% | 6.2% | 6.6% | 5.6% | 5.4% | −14.1% | −10.6% | 3.0% | −0.8% | 4.4% | −11.3% | −1.8% | −13.9% | −10.7% | −10.3% |
| Asset turnover | 0.70 | 0.70 | 0.63 | 0.60 | 0.59 | 0.60 | 0.59 | 0.47 | 0.36 | 0.42 | 0.47 | 0.37 | 0.46 | 0.46 | 0.53 | 0.58 | 0.66 | 0.69 |
| Current ratio | 2.74 | 3.65 | 1.40 | 1.20 | 1.44 | 1.85 | 2.51 | 2.27 | 2.10 | 1.86 | 2.01 | 1.31 | 1.47 | 1.62 | 1.38 | 1.10 | 1.51 | 1.63 |
| Debt to equity | 25.6% | 33.3% | 95.6% | 68.9% | 58.2% | 54.4% | 49.3% | 18.9% | 24.8% | 32.4% | 28.2% | 46.3% | 41.9% | 51.0% | 64.3% | 109.9% | 173.9% | 164.6% |
| Interest cover (operating income ÷ interest) | 17.4x | 15.2x | 6.9x | 6.7x | 8.5x | 9.5x | 6.7x | 12.7x | n/m | n/m | 11.8x | n/m | 10.0x | n/m | n/m | n/m | n/m | n/m |
| Effective tax rate | 24.5% | 24.9% | 4.3% | 2.7% | 14.1% | 20.1% | 23.4% | 2.2% | — | — | 24.3% | — | 24.6% | — | — | — | — | — |
| R&D as % of revenue | 2.3% | 3.0% | 3.4% | 2.9% | 2.9% | 2.8% | 2.8% | 3.4% | 3.8% | 4.0% | 3.6% | 3.7% | 4.0% | 4.4% | 4.6% | 4.4% | 4.1% | 4.6% |
| SG&A as % of revenue | 33.3% | 33.3% | 36.9% | 39.2% | 38.8% | 39.1% | 40.3% | 40.7% | 41.9% | 43.1% | 39.5% | 39.0% | 36.7% | 40.5% | 40.7% | 42.3% | 39.1% | 39.9% |
| Capital spending as % of revenue | 2.6% | 2.0% | 2.8% | 3.1% | 3.4% | 3.4% | 2.7% | 3.3% | 3.6% | 4.6% | 3.1% | 2.6% | 3.4% | 3.8% | 3.8% | 4.7% | 3.6% | 4.8% |
| Free cash flow ÷ net income | 111.6% | 125.4% | 131.8% | 88.4% | 101.4% | 142.7% | 169.3% | 102.0% | — | — | 201.6% | — | 125.3% | — | — | — | — | — |
| Dividends ÷ net income | 10.9% | 10.9% | 11.7% | 10.0% | 11.1% | 11.6% | 15.9% | 15.0% | — | — | 31.6% | — | 22.4% | — | — | — | — | — |
| Dividends and buybacks ÷ free cash flow | 35.5% | 75.9% | 33.6% | 25.3% | 48.1% | 43.5% | 35.9% | 200.4% | 104.8% | 103.8% | 66.1% | 40.6% | 56.7% | 69.0% | 182.5% | 133.8% | 123.1% | 67.1% |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Gross margin | 52.1% | 49.3% | 53.0% | 52.4% | 48.8% | 46.1% | 48.5% | 54.9% |
| Operating margin | −48.6% | −56.2% | 7.2% | −13.7% | −24.1% | −14.5% | −4.0% | 9.1% |
| Net margin | −51.9% | −47.5% | 2.3% | −4.8% | −47.2% | −15.2% | −1.1% | 4.1% |
| Free-cash-flow margin | 10.3% | 4.0% | −1.4% | 1.7% | 4.4% | 6.2% | −1.4% | 6.1% |
| Current ratio | 1.25 | 1.10 | 1.10 | 1.69 | 1.47 | 1.51 | 1.53 | 1.63 |
| Debt to equity | 89.0% | 109.9% | 116.2% | 122.6% | 162.0% | 173.9% | 169.7% | 164.6% |
| R&D as % of revenue | 4.2% | 4.6% | 4.1% | 4.0% | 4.1% | 4.2% | 5.0% | 5.0% |
| SG&A as % of revenue | 41.0% | 44.3% | 40.7% | 36.5% | 39.3% | 39.9% | 39.9% | 40.5% |
Financial health
- Short-term assets cover short-term liabilities $1.9bn of assets due within a year against $1.2bn of liabilities due within a year.
- Short-term assets cover long-term liabilities $1.9bn short-term assets against $2.7bn of longer-dated liabilities.
- More cash than debt $239m of cash against $2.2bn of debt.
- Debt below 40% of shareholders' equity Debt is 165% of equity.
- Debt burden no higher than five years ago Debt to equity moved from 38% to 165% over five years.
- A year's operating cash flow covers at least 20% of debt $319m of operating cash flow against $2.2bn of debt.
- Operating profit covers interest at least five times over Operating income of −$310m against $91m of interest.
Moat
Moderate moat
How hard Dentsply Sirona's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.
- Returns on capital 6 / 20
Cash operating profit has been a median 5.6% of total assets over 10 years.
- Pricing power 18 / 20
Gross margin has been a median 52.7%, moving by 1.6 percentage points (standard deviation) across 10 years.
- Durability 10 / 20
Operating margin has been a median -5.2%; its worst year was -28.2%.
- Cash conversion 14 / 20
Free cash flow was positive in 10 of 10 years, at a median 8.9% of revenue.
- Discipline 20 / 20
The diluted share count fell 9.0% over five years; stock-based pay has been a median 1.2% of revenue.
AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (67 before it).
Compare with peers
- West Pharmaceutical Services statistics
- Align Technology statistics
- The Cooper Companies statistics
- Envista Holdings Corp statistics
- ICU Medical Inc statistics
Head to head: WST vs XRAYALGN vs XRAYCOO vs XRAYNVST vs XRAY
More: Health Care Supplies stocks compared, Health Care sector, rankings of US companies